Reply to Comment on “Why do echinocandins fail? Identifying key predictors to improve clinical outcomes of Candida bloodstream infections: A retrospective multicenter cohort study”
Davide Fiore Bavaro(Humanitas University), Michele Bartoletti(University of Bologna), Valeria Cento(Rostov State Medical University), Laura De Santis(University of Bari Aldo Moro), Nadia Fusilli(IRCCS Humanitas Research Hospital), Giovanni Berna(Centro Cardiologico Monzino), Lidia Dalfino(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Alessandra Belati(Humanitas University), Luigi Ronga(University of Bari Aldo Moro), Lucia Diella(Humanitas University), Federica Tordato(Humanitas University), Paola Morelli(Humanitas University), Erminia Casari(IRCCS Humanitas Research Hospital), Monica Stufano(University of Bari Aldo Moro), Massimo Vanoni(IRCCS Humanitas Research Hospital), Maria Grazia Calabró(Vita-Salute San Raffaele University), Linda Bussini(University of Bologna), Annalisa Saracino(University of Bari Aldo Moro), Dario Cattaneo(ASST Fatebenefratelli Sacco), Francesco Di Gennaro(University of Bari Aldo Moro), Maurizio Cecconi(Humanitas University), Gianluca Castellani(IRCCS Humanitas Research Hospital), Salvatore Grasso(University of Bari Aldo Moro), Roberto Papale(University of Foggia), Sergio Carbonara(University of Bari Aldo Moro), Alessandro De Angelis(Humanitas University), Elena Costantini(IRCCS Humanitas Research Hospital)
Cited by 0
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine
|Intensive Care Medicine|2014|1.8k
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
|JAMA Internal Medicine|2020|1.7k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998